Silexion Therapeutics Submits Phase 2/3 Trial Application for SIL204 in Locally Advanced Pancreatic Cancer.

Silexion Therapeutics has submitted a Phase 2/3 clinical trial application to Israel for SIL204 in locally advanced pancreatic cancer. The submission follows successful toxicology studies and positive regulatory feedback in Germany, as well as strong preclinical data showing up to 99.7% cancer cell inhibition. Regulatory filings in Germany and the EU are planned for Q1 2026, with U.S. expansion anticipated following the safety run-in. The trial is expected to initiate in Q2 2026.